Search - tctmd.com

Displaying 1 - 20 of 75

Sort: Relevancy | Date

Presentation THT Abstracts 2026

From Pressure Data to Clinical Impact: CardioMEMS in Heart Failure with Preserved Ejection Fraction Management

Presenter: Gabriella Bayshtok

March 02, 2026

Presentation THT Abstracts 2026

Baseline NT-proBNP Predicts Outcomes After Transcatheter Edge-to-Edge Repair for Secondary Mitral Regurgitation with Preserved Ejection Fraction: The REPAIR Study

Presenter: Philipp von Stein

March 02, 2026

Presentation THT Abstracts 2026

Risk of Recurrence After Atrial Fibrillation Catheter Ablation in Heart Failure with Preserved Vs Reduced Ejection Fraction

Presenter: Nishanth Katukuri

March 02, 2026

Presentation ESC 2025

Vericiguat in ambulatory patients with chronic heart failure with reduced ejection fraction: Results of the VICTOR trial

Presenter: Faiez Zannad

August 30, 2025

Presentation ESC 2025

Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction: REBOOT

Presenter: Borja Ibanez

August 30, 2025

Presentation THT 2025

Win Ratio Analysis of Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure With Preserved Ejection Fraction: REBALANCE-HF Randomized Trial

Presenter: Marat Fudim

February 12, 2025

Presentation THT 2025

Myeloperoxidase Inhibition in Patients With Ischemic or Non-Ischemic Cardiomyopathy and Heart Failure With Reduced Ejection Fraction (MYSTERY-HF)

Presenter: Simon Braumann

February 12, 2025

Presentation THT 2025

Assessing Long-Term Outcomes of Tirzepatide and Semaglutide in Heart Failure With Preserved Ejection Fraction: A Retrospective Cohort Analysis From TrinetX Database

Presenter: Thitiphan Srikulmontri

February 12, 2025

Presentation THT 2025

Beta-Blocker Therapy and Long-Term Outcomes in Heart Failure With Reduced Ejection Fraction After Heart Transplantation: Real-World Evidence

Presenter: Thitiphan Srikulmontri

February 12, 2025

Presentation THT 2025

Impact of Sitagliptin on Long-Term Outcomes in Heart Failure With Reduced Ejection Fraction in Type 2 Diabetes Patients: A Retrospective Cohort Study

Presenter: Thitiphan Srikulmontri

February 12, 2025

Presentation THT 2025

Leveraging Remote Patient Monitoring to Optimize Guideline-Directed Medical Therapy in Heart Failure With Reduced Ejection Fraction

Presenter: Qianlan Xi

February 12, 2025

Presentation THT 2025

Is There a Role for Obesity in the Progression of Heart Failure With a Reduced Ejection Fraction?

Presenter: Javed Butler

February 12, 2025

Presentation THT 2025

Pressure-Volume Loop Derived Left Ventricular Hypercontractility Is Associated With Reduced Long-Term Survival in Heart Failure With Preserved Ejection Fraction

Presenter: Sebastian Roschx

February 12, 2025

Presentation THT 2025

Impact of SGLT2 Inhibitors on Mortality and Cardiovascular Admissions in Heart Failure With Reduced Ejection Fraction (HFrEF)

Presenter: Jonathan Zawadzki

February 12, 2025

Presentation THT Abstracts 2025

Beta-Blocker Therapy and Long-Term Outcomes in Heart Failure With Reduced Ejection Fraction After Heart Transplantation: Real-World Evidence

Presenter: Thitiphan Srikulmontri

February 11, 2025

Presentation THT Abstracts 2025

Leveraging Remote Patient Monitoring to Optimize Guideline-Directed Medical Therapy in Heart Failure With Reduced Ejection Fraction

Presenter: Qianlan Xi

February 11, 2025

Presentation THT Abstracts 2025

Baroreflex Activation Therapy Improves Cardiopulmonary Exercise Tolerance and Aerobic Capacity in Heart Failure With Reduced Ejection Fraction

Presenter: Dmitry Yaranov

February 11, 2025

Presentation THT Abstracts 2025

Evaluating Glucagon-Like Peptide Agonists and Glucose-Dependent Insulinotropic Polypeptide Receptor Agonists Treatment in Heart Failure With Preserved Ejection Fraction: A Meta-Analysis of Global RCTs

February 11, 2025

Presentation THT Abstracts 2025

Association of SGLT2 Inhibitors With Clinical Outcomes in Patients With Severe Renal Impairment (Estimated Glomerular Filtration Rate < 30) and Heart Failure With Reduced Ejection Fraction (HFrEF)

Presenter: Jonathan Zawadzki

February 11, 2025

Presentation THT Abstracts 2025

Impact of Sitagliptin on Long-Term Outcomes in Heart Failure With Reduced Ejection Fraction in Type 2 Diabetes Patients: A Retrospective Cohort Study

Presenter: Thitiphan Srikulmontri

February 11, 2025

Advertisement

From Pressure Data to Clinical Impact: CardioMEMS in Heart Failure with Preserved Ejection Fraction Management

Baseline NT-proBNP Predicts Outcomes After Transcatheter Edge-to-Edge Repair for Secondary Mitral Regurgitation with Preserved Ejection Fraction: The REPAIR Study

Risk of Recurrence After Atrial Fibrillation Catheter Ablation in Heart Failure with Preserved Vs Reduced Ejection Fraction

Vericiguat in ambulatory patients with chronic heart failure with reduced ejection fraction: Results of the VICTOR trial

Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction: REBOOT

Win Ratio Analysis of Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure With Preserved Ejection Fraction: REBALANCE-HF Randomized Trial

Myeloperoxidase Inhibition in Patients With Ischemic or Non-Ischemic Cardiomyopathy and Heart Failure With Reduced Ejection Fraction (MYSTERY-HF)

Assessing Long-Term Outcomes of Tirzepatide and Semaglutide in Heart Failure With Preserved Ejection Fraction: A Retrospective Cohort Analysis From TrinetX Database

Beta-Blocker Therapy and Long-Term Outcomes in Heart Failure With Reduced Ejection Fraction After Heart Transplantation: Real-World Evidence

Impact of Sitagliptin on Long-Term Outcomes in Heart Failure With Reduced Ejection Fraction in Type 2 Diabetes Patients: A Retrospective Cohort Study

Leveraging Remote Patient Monitoring to Optimize Guideline-Directed Medical Therapy in Heart Failure With Reduced Ejection Fraction

Is There a Role for Obesity in the Progression of Heart Failure With a Reduced Ejection Fraction?

Pressure-Volume Loop Derived Left Ventricular Hypercontractility Is Associated With Reduced Long-Term Survival in Heart Failure With Preserved Ejection Fraction

Impact of SGLT2 Inhibitors on Mortality and Cardiovascular Admissions in Heart Failure With Reduced Ejection Fraction (HFrEF)

Beta-Blocker Therapy and Long-Term Outcomes in Heart Failure With Reduced Ejection Fraction After Heart Transplantation: Real-World Evidence

Leveraging Remote Patient Monitoring to Optimize Guideline-Directed Medical Therapy in Heart Failure With Reduced Ejection Fraction

Baroreflex Activation Therapy Improves Cardiopulmonary Exercise Tolerance and Aerobic Capacity in Heart Failure With Reduced Ejection Fraction

Evaluating Glucagon-Like Peptide Agonists and Glucose-Dependent Insulinotropic Polypeptide Receptor Agonists Treatment in Heart Failure With Preserved Ejection Fraction: A Meta-Analysis of Global RCTs

Association of SGLT2 Inhibitors With Clinical Outcomes in Patients With Severe Renal Impairment (Estimated Glomerular Filtration Rate < 30) and Heart Failure With Reduced Ejection Fraction (HFrEF)

Impact of Sitagliptin on Long-Term Outcomes in Heart Failure With Reduced Ejection Fraction in Type 2 Diabetes Patients: A Retrospective Cohort Study

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content